After Needham and Barclays gave Sarepta Therapeutics (NASDAQ: SRPT) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics today and set a price target of $267. The company’s shares closed yesterday at $138.80.
Chattopadhyay noted:
“Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.81, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.8%, and tax rate of 15% beginning in FY 2024.”
According to TipRanks.com, Chattopadhyay has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.4% and a 37.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
Sarepta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $198.06, representing a 42.7% upside. In a report issued on October 12, Bernstein also initiated coverage with a Buy rating on the stock with a $170 price target.
.
See today’s analyst top recommended stocks >>
Based on Sarepta Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $109 million. In comparison, last year the company had a GAAP net loss of $47.73 million.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRPT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.
